Rapid Immunoassay Analyzers Market Report 2026

The rapid immunoassay analyzers market size has grown rapidly in recent years. It will grow from $1.23 billion in 2025 to $1.36 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to growing prevalence of infectious and chronic diseases, rising demand for early and rapid disease diagnosis, increasing adoption of point of care testing solutions, expansion of diagnostic laboratory infrastructure, growing awareness regarding preventive healthcare and routine screening.

The rapid immunoassay analyzers market size is expected to see rapid growth in the next few years. It will grow to $2.08 billion by 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing development of next-generation biomarker detection technologies, rising investment in decentralized healthcare diagnostics, growing demand for home-based diagnostic testing solutions, expansion of automated laboratory testing systems, increasing integration of digital health monitoring and connected diagnostic platforms. Major trends in the forecast period include increasing adoption of rapid point of care diagnostic testing solutions, growing demand for portable and handheld immunoassay analyzers, rising utilization of multiplex testing for infectious disease detection, expansion of high-throughput automated immunoassay systems in laboratories, increasing focus on fast turnaround time and accurate clinical diagnostics.

The increasing prevalence of infectious and chronic diseases is expected to propel the growth of the rapid immunoassay analyzers market going forward. Infectious and chronic diseases are medical conditions caused by pathogenic microorganisms or long-term physiological disorders that require continuous monitoring and timely diagnosis. The prevalence of infectious and chronic diseases is increasing due to aging populations. The rapid immunoassay analyzers market is supported by the rising prevalence of infectious and chronic diseases, as these systems provide rapid and reliable diagnostic results that enable early detection, timely treatment, and effective disease monitoring. For instance, in April 2025, according to the Centers for Disease Control and Prevention, in 2023, approximately 76.4% of U. S. adults reported having at least one of 12 selected chronic conditions, while 51.4% of U. S. adults reported multiple chronic conditions. Therefore, the increasing prevalence of infectious and chronic diseases is driving the growth of the rapid immunoassay analyzers market.

Leading companies operating in the rapid immunoassay analyzers market are concentrating on portable diagnostic technologies, such as handheld fluorescence immunoassay analyzers, to reduce testing turnaround time and improve cost efficiency in decentralized healthcare settings. Handheld fluorescence immunoassay analyzers refer to compact diagnostic devices that utilize fluorescence-labeled antibodies to detect specific biomarkers with high sensitivity and deliver rapid results at the point of care without requiring centralized laboratory infrastructure. For instance, in November 2025, Boditech Med Inc. introduced its expanded point-of-care diagnostic product lineup at MEDICA 2025. The solution portfolio includes portable immunoassay systems with simplified workflows and short testing times, which improve operational efficiency. It also supports both automated and manual formats, which enhances flexibility in low-resource settings and reduces infrastructure-related costs.

In January 2025, bioMérieux acquired SpinChip Diagnostics for an undisclosed amount. Through this acquisition, bioMérieux aims to strengthen its point-of-care testing portfolio by integrating rapid immunoassay platform technology, enabling faster and more accurate diagnostic results closer to patients and expanding its presence in decentralized healthcare settings. SpinChip Diagnostics is a Norway-based provider of rapid immunoassay diagnostic platforms developed for near-patient testing, offering high-sensitivity results within minutes using compact, automated systems.

Major companies operating in the rapid immunoassay analyzers market are Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, BioMérieux S. A., Quidelortho Corporation, Tecan Trading AG, DiaSorin S. p. A., Euroimmun Medizinische Labordiagnostika AG, Autobio Diagnostics Co. Ltd., EKF Diagnostics, Boditech Med Inc., Dynex Technologies Inc., QuantuMDx Group Ltd., NanoEntek, J. Mitra & Co. Pvt. Ltd., Baebies, Micropoint Bioscience, Coris BioConcept, MiCo BioMed Inc., Abionic SA, ANP Technologies Inc., Epitope Diagnostics Inc., MedMira Inc., Nanōmix Inc.

North America was the largest region in the rapid immunoassay analyzers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rapid immunoassay analyzers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the rapid immunoassay analyzers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rapid immunoassay analyzers market consists of sales of benchtop immunoassay analyzers, portable immunoassay analyzers, fully automated immunoassay systems, semi-automated analyzers, lateral flow assay readers, fluorescence immunoassay analyzers, chemiluminescence immunoassay analyzers, and multiplex immunoassay systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.